This study aimed to observe the effect of the direct-acting antiviral (DAA) therapy on liver stiffness (LS) and serum biomarkers. We prospectively observed 35 patients with chronic hepatitis C infection and attained a sustained virological response (SVR) after antiviral therapy. Shear wave elastography (SWE) measurement was performed at the beginning of DAA treatment and at 48 weeks after the end of treatment (EOT48w). The METAVIR score and the score for varices needing treatment (VNT) were determined based on the LS values; the fibrosis-4 (FIB4) score was calculated from laboratory tests. The baseline LS (mean ± standard deviation = 2.59 ± 0.89 m/s) decreased significantly after successful DAA therapy (1.90 ± 0.50 m/s; p < 0.001). The METAVIR score showed significant improvement at EOT48w (F0/1 = 9, F2 = 2, F3 = 10, F4 = 14) compared to the initial status (F0/1 = 2, F2 = 1, F3 = 7, F4 = 25; p < 0.028). The FIB4 score indicated less fibrosis after therapy (2.04 ± 1.12) than at baseline (3.51 ± 2.24; p < 0.018). Meanwhile, the number of patients with a high-risk of VNT was significantly less at EOT48w (4 vs. 15 at baseline; OR = 0.17 95% confidence interval (CI) = 0.05–0.59, p < 0.007). SWE indicates a significant resolution of liver fibrosis when chronic hepatitis C patients are in SVR, coinciding with a lower risk of VNT.

中文翻译：

---

持续性病毒学应答增强对慢性丙型肝炎患者肝硬挺度的剪切波弹性成像随访临床风险评估

这项研究旨在观察直接作用抗病毒（DAA）治疗对肝脏僵硬（LS）和血清生物标志物的影响。我们前瞻性地观察了35例慢性丙型肝炎感染患者，并在抗病毒治疗后获得了持续的病毒学应答（SVR）。在DAA治疗开始时和治疗结束后48周（EOT48w）进行剪切波弹性成像（SWE）测量。根据LS值确定METAVIR评分和需要治疗的静脉曲张评分（VNT）。纤维化4（FIB4）分数是根据实验室测试计算得出的。成功进行DAA治疗后，基线LS（平均值±标准差= 2.59±0.89 m / s）显着降低（1.90±0.50 m / s; p<0.001）。与初始状态（F0 / 1 = 2，F2 = 1，F3 = 7，F4 = 25）相比，METAVIR得分在EOT48w（F0 / 1 = 9，F2 = 2，F3 = 10，F4 = 14）上有显着改善。 ; p <0.028）。FIB4评分显示治疗后的纤维化程度（2.04±1.12）低于基线时的（3.51±2.24；p <0.018）。同时，在EOT48w时具有高VNT风险的患者人数明显减少（基线时为4比15； OR = 0.17，95％置信区间（CI）= 0.05-0.59，p <0.007）。当慢性丙型肝炎患者处于SVR时，SWE表明肝纤维化的显着缓解，这与较低的VNT风险相吻合。